![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Publisher: Adis International
ISSN: 1173-8324
Source: Inpharma, Vol.1, Iss.1598, 2007-01, pp. : 1-1
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Certolizumab pegol: a guide to its use in Crohn's disease
Drugs & Therapy Perspectives, Vol. 23, Iss. 11, 2007-11 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Certolizumab pegol a PRECiSE treatment for Crohn's disease
Inpharma, Vol. 1, Iss. 1547, 2006-01 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Can certolizumab pegol cure Crohn's disease?
Inpharma, Vol. 1, Iss. 1615, 2007-01 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Infliximab maintenance therapy valuable strategy in Crohn's disease.
Inpharma, Vol. 1, Iss. 1313, 2001-01 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Certolizumab pegol RAPIDly rising in RA
Inpharma, Vol. 1, Iss. 1597, 2007-01 ,pp. :